Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥512.00 - ¥764.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)50.89K

Market Cap

¥5.58B

Enterprise Value¥2.22B

Total Cash (Recent Filing)¥2.70B

Total Debt (Recent Filing)¥766.00M

Price to Earnings (P/E)―

Beta0.54

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-101.10

Shares Outstanding10,091,200

10 Day Avg. Volume43,580

30 Day Avg. Volume50,893

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthA >200% YoY revenue rebound signals renewed commercial traction for the scaffold-free 3D cell assembly platform. Sustained top-line recovery improves scale economics, supports incremental R&D and commercialization spend, and increases the probability of converting fixed costs into operating leverage over time.

Product EconomicsA positive gross margin (~34%) indicates underlying product and service economics that can support a viable business model. If revenue growth continues, these unit economics provide a foundation to absorb SG&A and R&D, enabling a realistic path toward improving operating margins long-term.

Manageable LeverageLeverage below 0.5 and a sizable equity base give the company room to finance near-term operations and R&D without acute solvency stress. This balance sheet capacity reduces immediate refinancing risk and provides flexibility to pursue partnerships or incremental funding while scaling commercialization efforts.

Bears Say

Deep UnprofitabilityExtremely large negative EBIT and net margins reflect structural unprofitability that undermines long-term resilience. Persistent heavy losses increase reliance on external capital, risk shareholder dilution, and mean management must deliver sustained margin improvement to avoid recurring refinancing and viability risks.

Weak Cash GenerationConsistently negative operating cash flow and free cash flow show the business cannot self-fund operations or growth. Ongoing cash burn forces dependence on financing or equity raises, which can dilute shareholders or increase leverage, and limits ability to make long-term investments without secured funding.

Unscalable Cost StructureProfitability has materially deteriorated since 2021, with operating losses far outpacing revenues. This suggests the current cost base and go-to-market model are not yet scalable; absent durable cost reductions or higher-margin revenue mix, revenue rebounds may not translate into lasting profitability.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥512.00 and its highest was ¥764.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥5.58B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Aug 19, 2026 which is in 47 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on May 15, 2026. The company reported -¥22.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥22.56.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,091,200 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥22.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.622%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.